Altre lingue Aldeyra Therapeutics, Inc.

Azioni

ALDX

US01438T1060

Tempo reale stimato Cboe BZX Altri mercati azionari 19:56:06 08/07/2024			Variaz. 5gg	Var. 1 gen.
3,24 ^USD	+1,57%		-1,08%	-8,40%

20/06	Transcript : Aldeyra Therapeutics, Inc. - Special Call
20/06	Aldeyra Therapeutics annuncia l'avanzamento dei nuovi modulatori RASP e i recenti dati preclinici nell'obesità alla Tavola Rotonda degli Investitori 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) added to Russell Small Cap Comp Value Index	01/07
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) added to Russell 3000 Value Index	01/07
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) added to Russell 2500 Value Index	01/07
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) added to Russell 2000 Value Index	01/07
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) added to Russell Microcap Value Index	01/07
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) added to Russell 3000E Value Index	01/07
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable	20/06
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable	20/06
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease	13/06
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease	13/06
Aldeyra Therapeutics to Host Investor Roundtable Q&A	12/06
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference	29/05
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study	08/05
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease	08/05
Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease	08/05
Aldeyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day	25/04
Aldeyra Therapeutics to Host Research and Development Day on April 25, 2024	19/04
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024	18/04
North American Morning Briefing : Focus Turns to -2-	04/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Aldeyra Therapeutics, Inc.

Azioni

ALDX

US01438T1060

Altre lingue

Filtri